Methicillin-resistant staphylococcus aureus (MRSA) is an antibiotic-resistant infection that has historically been difficult to treat. However, studies at Brown University and Rhode Island hospitals have proven that an FDA-approved drug used to treat tapeworm was able to curb growth of MRSA bacteria in vitro and in nematode populations. Since it has already been approved and its patent has expired, this tapeworm drug is the ideal candidate for repurposing. The next step in the research process will be tests on rodents to look for systemic side effects.


MD Magazine
See article in PLoS ONE here